Every Form 4 that Kala Pharmaceuticals Inc (KALA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KALA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KALA filings page.
KALA BIO, Inc. disclosed that Chief Executive Officer and director David E. Lazar entered into a securities purchase agreement to invest in the company through convertible preferred stock. On November 24, 2025, he acquired 900,000 shares of Series AA Convertible Non-Redeemable Preferred Stock at $2.00 per share, for a total of $1,800,0002,100,000 shares of Series AAA Convertible Non-Redeemable Preferred Stock at $2.00 per share, for an additional $4,200,000.
Each share of Series AA Preferred is convertible into 55 shares of common stock and each Series AAA share into 420 shares, in both cases subject to ownership limits. None of the preferred shares can be converted until stockholders approve an increase in authorized capital and the conversion terms in line with Nasdaq listing rules. The Series AA Preferred Stock is perpetual and has no expiration date, and Lazar reports no common stock currently beneficially owned.
KALA BIO (KALA) disclosed an insider transaction by a director. On 10/23/2025, the reporting person sold 154,894 shares of common stock at a $0.81 weighted average price, with individual trades executed between $0.78 and $0.85. Following the sale, the reporting person beneficially owns 103,540 shares, reported as unvested RSUs, held directly.
The filing notes the price is a weighted average and that detailed trade breakdowns within the stated range are available upon request.
KALA BIO (KALA) reported insider transactions by its Chief Financial Officer, Mary Reumuth. On 10/22/2025, she sold 32,230 shares of common stock at a weighted average price of $0.83, with individual trades ranging from $0.82 to $0.84. On 10/23/2025, she sold an additional 967 shares at $0.82.
Following these transactions, her reported beneficial ownership was 29,873 shares after the first sale and 28,906 shares after the second sale, held directly. A footnote states the 28,906 balance includes unvested RSUs.
KALA BIO (KALA) reported an insider stock transaction on a Form 4. A director sold 47,768 shares of common stock on 10/22/2025 at a weighted average price of $0.83, with individual trades ranging from $0.82 to $0.85.
After the sale, the reporting person beneficially owned 35,932 shares directly, which includes 35,732 unvested RSUs, and 1 share indirectly held by a son.
KALA BIO (KALA) reported a Form 4 showing an officer transaction. On 10/22/2025, an officer sold 46,748 shares of common stock at a weighted average price of $0.83, with trade prices ranging from $0.82 to $0.85. Following the sale, 35,952 shares were listed as beneficially owned. A footnote states this figure includes 35,952 unvested RSUs. The reporting person’s role is noted as Head of Research and Development and Chief Medical Officer, and the ownership form is Direct.
KALA BIO (KALA) reported an insider transaction by its Chief Business Officer. On 10/22/2025, the officer sold 20,806 shares of common stock at a $0.83 weighted average price, with trades ranging from $0.82 to $0.84. Following the sale, the officer beneficially owned 41,760 shares directly.
The reported balance includes 28,878 unvested RSUs, which are awards that may settle in shares as they vest. The filing lists direct ownership and does not indicate joint or group filing.
Baker Bros. reporting persons filed a Form 4 disclosing multiple sales of KALA BIO, Inc. (KALA) common stock on 09/30/2025 and 10/01/2025. The filing shows four separate dispositions: 21,376 and 195,425 shares on 09/30/2025 at a weighted average price of $1.5959, and 50,640 and 462,967 shares on 10/01/2025 at a weighted average price of $1.3838. After each reported transaction, the filings list the number of shares beneficially owned by the reporting entities and individuals on an indirect basis. Footnotes state the trading occurred through the Funds (667, L.P. and Baker Brothers Life Sciences, L.P.) across price ranges of $1.50–$1.84 and $1.27–$1.48, and clarify the Adviser and certain partners disclaim beneficial ownership except for pecuniary interest.